« Previous
Next »
Titles
- Belimumab and voclosporin for lupus nephritis: effectiveness and value : final report1
- Bempedoic acid and inclisiran for patients with heterozygous familial hypercholesterolemia and for secondary prevention of ASCVD: Effectiveness and value : final report1
- Eculizumab and efgartigimod for the treatment of myasthenia gravis: effectiveness and value : final report1
- Esketamine for the treatment of treatment-resistant depression: effectiveness and value : final evidence report1
- Gene therapy for hemophilia B and an update on gene therapy for hemophilia A: effectiveness and value : final evidence report1
- JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value : final evidence report1
- Lecanemab for early Alzheimer’s disease: final evidence report1
- Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: effectiveness and value : final evidence report1
- Special assessment of outpatient treatments for COVID-19: nirmatrelvir/ritonavir (Paxlovid) health-benefit price benchmark update1
- Treatments for anemia in chronic kidney disease: effectiveness and value : final evidence report1
- Unsupported price increase report: 2020 assessment1
- Valoctocogene roxaparvovec and emicizumab for hemophilia A without inhibitors: effectiveness and value : final report1